Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New patients: should children be treated differently?

M C Dubinsky1

  • 1Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. Marla.Dubinsky@cshs.org

Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland
|April 6, 2006
PubMed
Summary

Childhood inflammatory bowel disease (IBD) poses significant risks, including malnutrition and developmental issues. Effective management is crucial to prevent long-term complications and ensure remission, with newer therapies showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.

Current medicinal chemistry·2017
Same author

Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them? Authors' reply.

Alimentary pharmacology & therapeutics·2016
Same author

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.

Alimentary pharmacology & therapeutics·2015
Same author

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.

Alimentary pharmacology & therapeutics·2013
Same author

Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes.

Alimentary pharmacology & therapeutics·2007
Same author

Diagnostic markers of inflammatory bowel disease.

Current opinion in gastroenterology·2006

Area of Science:

  • Pediatric Gastroenterology
  • Chronic Disease Management

Background:

  • Childhood inflammatory bowel disease (IBD) is a serious chronic gastrointestinal condition impacting growth and development.
  • Children with IBD face increased risks of malnutrition, growth failure, bone demineralization, and psychosocial challenges.

Observation:

  • Current treatments for pediatric IBD include 5-ASA, antibiotics, corticosteroids, nutritional therapy, and immunomodulators.
  • Long-term corticosteroid use is discouraged due to risks of bone demineralization and growth failure.
  • A case report highlights diagnostic challenges and the need for optimized therapy in pediatric IBD.

Findings:

  • Newer treatments like infliximab demonstrate efficacy in inducing and maintaining remission for Crohn's disease in children.
  • Paediatric use of infliximab is expected to rise.

Related Experiment Videos

Implications:

  • Optimizing medical management is essential to prevent severe long-term complications in children with IBD.
  • Adopting advanced therapies may improve treatment outcomes and quality of life for pediatric patients.